Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...
Craig-Hallum raised the firm’s price target on CVRx (CVRX) to $22 from $20 and keeps a Buy rating on the shares. CVRx posted a modest beat in ...
CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hosted on MSN2d
William Blair Upgrades CVRx (CVRX)Fintel reports that on January 14, 2025, William Blair upgraded their outlook for CVRx (NasdaqGS:CVRX) from Market Perform to ...
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
William Blair analyst Margaret Kaczor upgraded CVRx (CVRX) to Outperform from Market Perform.Stay Ahead of the Market:Discover outperforming ...
CVRx anticipates a 35% increase in Q4 2024 revenue and a 30% increase in FY24 revenue, with shares down 1.55% premarket.
CAMP4 Therapeutics Corporation ("CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to ...
Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to ...
Vensana Capital recently announced that it has closed a $425 million Fund III for continued investment in innovative medtech ...
Vensana Capital Closes $425 Million Fund III to Back Breakthrough Medical Technology Companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback